We are advising the company on the funding round

Davis Polk is advising Bit Bio Limited in connection with its $25 million series D funding round, which includes backing from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The funding will support the company’s portfolio expansion and wider customer access.

bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. M&G Investments is part of M&G plc, a savings and investments company with £387 billion of assets under management, as of 30 June 2026. M&G plc has customers in the United Kingdom, Europe, the Americas and Asia, including individual savers and investors, life insurance policy holders and pension scheme members. M&G has invested through its Crossover strategy within its public equity business on behalf of M&G Life’s £138 billion With Profits Fund and its 4.5 million UK policyholders. Crossover provides patient growth equity to high-quality, fast-growing private companies, enabling their eventual crossover into public markets.

The Davis Polk corporate team includes counsel William Tong and associate Federica Camilleri de Marco. Both members of the Davis Polk team are based in the London office.

Copy link to share post